The fifth-largest pharmaceutical company in the world has deployed more than 3,500 Nvidia Blackwell GPUs.

F. Hoffmann-La Roche AG, more commonly known as Roche, said that it operates the chips across hybrid cloud and on‐premises environments in the US and Europe. It claims that the figure is "the greatest announced GPU footprint available to a pharmaceutical company."

The GPU deployment is an expansion of a 2023 partnership between Nvidia and Roche subsidiary Genentech, where the two companies worked together to optimize Genentech’s proprietary machine learning algorithms and models on Nvidia DGX Cloud.

The new compute will be used for biological foundation models, drug discovery, and digital twins for manufacturing.

“We’re excited to innovate at the intersection of science and technology to accelerate drug and diagnostic solutions development,” said Wafaa Mamilli, chief digital and technology officer at Roche.

“With high-quality data and smarter AI, we will be able to leverage those insights both in pharma as well as in our diagnostic divisions.”